PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

Platinum Sensitive ◽

A cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.027 ◽

2018 ◽

Vol 149 ◽

pp. 9 ◽

Cited By ~ 1

Author(s):

A.Y. Liu ◽

J.G. Cohen ◽

C. Walsh ◽

C.H. Holschneider ◽

A.K. Sinno

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitors ◽

Platinum Sensitive ◽

A Cost-Effectiveness Analysis of Three PARP Inhibitors for Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.07.025 ◽

2017 ◽

Vol 147 (1) ◽

pp. 196 ◽

Cited By ~ 5

Author(s):

A.Y. Liu ◽

J.G. Cohen ◽

C.S. Walsh ◽

C.H. Holschneider ◽

A.K. Sinno

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitors ◽

Platinum Sensitive ◽

Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.08.003 ◽

2020 ◽

Vol 159 (2) ◽

pp. 483-490 ◽

Cited By ~ 1

Author(s):

Rafael Gonzalez ◽

Laura J. Havrilesky ◽

Evan R. Myers ◽

Angeles Alvarez Secord ◽

Joseph A. Dottino ◽

...

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Parp Inhibitors ◽

Advanced Stage ◽

Newly Diagnosed ◽

Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1954506 ◽

2021 ◽

Author(s):

John Hang Leung ◽

Hui-Chu Lang ◽

Shyh-Yau Wang ◽

Hsueh Fang Lo ◽

Agnes LF Chan

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Platinum Sensitive ◽

Management of platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

Gynecologic Oncology ◽

10.1016/j.ygyno.2007.06.029 ◽

2007 ◽

Vol 107 (2) ◽

pp. 211-218 ◽

Cited By ~ 18

Author(s):

L HAVRILESKY ◽

A SECORD ◽

S KULASINGAM ◽

E MYERS

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Platinum Sensitive ◽

Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost-effectiveness analysis of the AURELIA trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.04.116 ◽

2016 ◽

Vol 141 ◽

pp. 36

Author(s):

W.Z. Wysham ◽

E.M. Schaffer ◽

T.M. Coles ◽

D.R. Roque ◽

S.B. Wheeler ◽

...

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Single Agent ◽

Effectiveness Analysis ◽

Platinum Resistant ◽

Single Agent Chemotherapy

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Journal of Gynecologic Oncology ◽

10.3802/jgo.2022.33.e12 ◽

2022 ◽

Vol 33 ◽

Author(s):

Junsik Park ◽

Myong Cheol Lim ◽

Jae-Kwan Lee ◽

Dae Hoon Jeong ◽

Se Ik Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Platinum Sensitive ◽

Previously Treated

Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort

Annals of Oncology ◽

10.1093/annonc/mdy285.193 ◽

2018 ◽

Vol 29 ◽

pp. viii351-viii352

Author(s):

J.R. Gallagher ◽

K.J. Heap ◽

S. Carroll

Keyword(s):

Ovarian Cancer ◽

Clinical Trial ◽

Adverse Events ◽

Observational Study ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Dose Cohort ◽

Platinum Sensitive ◽

Starting Dose

Cost-effectiveness of homologous recombination defect testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.223 ◽

2012 ◽

Vol 125 ◽

pp. S92-S93 ◽

Cited By ~ 1

Author(s):

A. Alvarez-Secord ◽

J. Barnett ◽

J. Ledermann ◽

B. Peterson ◽

E. Myers ◽

...

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Homologous Recombination ◽

Parp Inhibitor ◽

Platinum Sensitive

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum Sensitive< Recurrent Ovarian Cancer

Value in Health ◽

10.1016/j.jval.2018.04.185 ◽

2018 ◽

Vol 21 ◽

pp. S29

Author(s):

L Zhong ◽

AT Tran ◽

T Tomasino ◽

JA Smith ◽

EK Nugent

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Platinum Sensitive